Proton Pump Inhibitors (Prilosec, Nexium, et. al.) may be linked to an increased risk of kidney disease

“If you take omeprazole Prilosec or The Purple Pill that is heavily advertised, consider switching to a non-PPI drug. Called H-2-receptor blockers, these medications include cimetidine (Tagamet HB), famotidine (Pepcid AC), nizatidine (Axid AR) or ranitidine (Zantac).” Bill Chesnut, MD

To go back to New Health News: http://billchesnutmd.com/new-health-news

PPIs may be linked to an increased risk of CKD, study reveals  AMA Morning Rounds, April 15, 2016.

ABC World News Tonight (4/14, story 10, 0:25, Muir) reported that a study has linked “proton pump inhibitors including Nexium [esomeprazole magnesium] and Prilosec [omeprazole] to an increased risk of chronic kidney disease [CKD].”

According to CNN (4/14, Christensen), some “173,321 people who used PPIs and 20,270” who “took a PPI alternative known as histamine H2 receptor blockers” were included in the five-year study.

The CBS News (4/14, Welch) website reports that “over five years of follow-up…15 percent of people using PPIs were diagnosed with chronic kidney disease, versus 11 percent of those on H2-blockers,” which “translated to a 28 percent increased risk of developing kidney disease for PPI users.” While just “a few patients in the study – less than 0.2 percent – developed end-stage kidney failure. The risk was 96 percent higher for those on PPIs.” The study was published online in the Journal of the American Society of Nephrology.